The idea behind PGXL’s PerMIT is that software can, indeed, make drugs more effective. The key is incorporating fine-grained patient information, including genetic data, into an algorithm that models patient-specific reactions to different treatment regiments.This gives the physician the tools to find the most effective treatment for a patient, without putting the patient at risk.
Today, the first data from the development of PGXL’s PerMIT software are published in the journal Thrombosis and Haemostasis, and the results are promising. We won’t go into detail here, but this article summary says a lot:
These pilot data suggest that the PerMIT method and its incorporation of genotype/phenotype information may help practitioners increase the safety, efficacy, and efficiency of warfarin therapeutic management.
So, yes, we believe software can make drugs more effective, and we think in the next few years you’re going to be hearing a lot about this “companion informatic™” approach to diagnosis and treatment.
An approach pioneered right here are PGXL.